Heart risks linked to diabetes drugJune 29th, 2010 - 2:57 pm ICT by ANI
Washington, June 29 (ANI): A recent study has revealed that the use of diabetes drug rosiglitazone is associated with an increased risk for heart attack.
Rosiglitazone was approved in 1999 to treat hyperglycemia (high blood glucose levels) among patients with type 2 diabetes. Concerns about the cardiovascular safety of rosiglitazone first arose in 2007, when a meta-analysis demonstrated a significantly increased risk for myocardial infarction (heart attack) and a borderline significant increase for cardiovascular death.
No large, definitive cardiovascular outcomes trials have been conducted with rosiglitazone. However, as a consequence of a 2004 court settlement in New York, GSK was required to post clinical trial results on a public web site.
In the combined studies, rosiglitazone therapy was associated with a significantly increased risk of myocardial infarction by an estimated 28 percent to 39 percent, although the risk of cardiovascular death was not increased.
“An alternative analysis that included trials with no cardiovascular events found a similar hazard. Subgroups classified by study duration and comparator drug also showed elevated odds ratio estimates,” the authors said.
“These findings are consistent with prior meta-analyses conducted by GSK, the FDA and most independent investigators demonstrating an increased risk of myocardial infarction in patients treated with rosiglitazone.
“The FDA has announced that it will conduct an advisory committee meeting in July 2010 to consider whether to remove rosiglitazone from the market,” they added.
The mechanisms by which rosiglitazone may cause cardiovascular harm are not clear, the authors note, but could involve increases in low-density lipoprotein (LDL, or “bad” cholesterol) levels or genetic effects associated with the production of an enzyme linked to plaque rupture.
The study appears in the July 26 print issue of Archives of Internal Medicine. (ANI)
- No link between diabetes drug and rise in heart attacks - Jun 30, 2010
- Mediterranean diet a sound recipe for healthy living - Mar 08, 2011
- More strokes, fewer heart attacks with carotid stents: Study - Oct 12, 2010
- Scientists find 13 new genes linked to heart diseases - Mar 07, 2011
- Drug used to treat type 2 diabetes linked to heart problems - Mar 18, 2011
- Post-menopause, women more vulnerable to heart attacks - Jun 12, 2012
- Meta-analysis shows folic acid supplements not beneficial for heart - Oct 12, 2010
- Diabetes drug may elevate bladder cancer risk - Jul 04, 2012
- Two-fold increased risk of heart attack in rheumatoid arthritis patients - Jun 19, 2010
- Calcium supplements' link to heart attack risk 'overstated' - Jul 31, 2010
- Sodas, other sugary beverages linked to diabetes risk - Oct 28, 2010
- Popular diabetes drugs 'increase risk for fractures in patients' - Jul 30, 2010
- New study raises questions over broader use of statins - Jun 29, 2010
- Gene-silencing that could prevent diabetes-related heart failure - Dec 10, 2010
- FDA approves personalized therapy for tough-to-treat colorectal cancer - Jul 26, 2012
Tags: archives of internal medicine, bad cholesterol, blood glucose levels, cardiovascular death, cardiovascular events, cardiovascular outcomes, cholesterol levels, court settlement, diabetes drug rosiglitazone, genetic effects, high blood glucose, high blood glucose levels, independent investigators, low density lipoprotein, meta analysis, myocardial infarction, odds ratio, plaque rupture, study duration, type 2 diabetes